Galectin-1: A link between tumor hypoxia and tumor immune privilege

Journal of Clinical Oncology

Volumn 23, Issue 35, 2005, Pages 8932-8941

  Le, Quynh Thu ^a   Shi, Gongyi ^a   Cao, Hongbin ^a   Nelson, Daniel W ^a   Wang, Yingyun ^a   Chen, Eunice Y ^a   Zhao, Shuchun ^a   Kong, Christina ^a   Richardson, Donna ^a   O'Byrne, Ken J ^a   Giaccia, Amato J ^a   Koong, Albert C ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CD3 ANTIGEN; GALECTIN 1;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TUMOR IMMUNITY; XENOGRAFT; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; CELL HYPOXIA; DISEASE COURSE; ENZYME IMMUNOASSAY; HEAD AND NECK TUMOR; IMMUNOLOGY; MASS SPECTROMETRY; METABOLISM; MOUSE MUTANT; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STAINING; SURVIVAL; T LYMPHOCYTE; TUMOR CELL LINE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE PROGRESSION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GALECTIN 1; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, SCID; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STAINING AND LABELING; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 33144460217     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.0206     Document Type: Article

References (41)

1. Yun Z, Giaccia AJ: Tumor deprivation of oxygen and tumor suppressor gene function. Methods Mol Biol 223:485-504, 2003
2. Brizel DM, Dodge RK, Clough RW, et al: Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53:113-117, 1999
3. Nordsmark M, Overgaard J: A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57:39-43, 2000
4. Koong AC, Denko NC, Hudson KM, et al: Candidate genes for the hypoxic tumor phenotype. Cancer Res 60:883-887, 2000
5. Lal A, Peters H, St Croix B, et al: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93:1337-1343, 2001
6. Romero-Ramirez L, Cao H, Nelson D, et al: XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res 64:5943-5947, 2004
7. Chen Y, Shi G, Xia W, et al: Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling. Cancer Res 64:7302-7310, 2004
8. Soltys SG, Le QT, Shi G, et al: The use of plasma surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 10:4806-4812, 2004
9. Nelson DW, Cao H, Zhu Y, et al: A non-invasive approach for assessing tumor hypoxia in xenografts: Developing a urinary marker for hypoxia. Cancer Res 65:6151-6158, 2005
10. Liu CL, Prapong W, Natkunam Y, et al: Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 161:1557-1565, 2002
11. Swinson DE, Jones JL, Richardson D, et al: Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21:473-482, 2003
12. Sobin LH, Hermanek P, Hutter RV: TNM classification of malignant tumors: A comparison between the new (1987) and the old editions. Cancer 61:2310-2314, 1988
13. Terris DJ, Dunphy EP: Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg 120:283-287, 1994
14. Glanz SA, Slinker BK: Primer of Applied Regression Analysis of Variance. New York, NY, McGraw-Hill Inc, 1990
15. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
16. Wykoff CC, Beasley NJ, Watson PH, et al: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075-7083, 2000
17. Beasley NJ, Wykoff CC, Watson PH, et al: Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61:5262-5267, 2001
18. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7:3399-3403,2001
19. Perillo NL, Pace KE, Seilhamer JJ, et al: Apoptosis of T cells mediated by galectin-1. Nature 378:736-739, 1995
20. 2O. Rubinstein N, Alvarez M, Zwirner NW, et al: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: A potential mechanism of tumor-immune privilege. Cancer Cell 5:241-251, 2004
21. Yang RY, Liu FT: Galectins in cell growth and apoptosis. Cell MoI Life Sei 60:267-276, 2003
22. Liu FT, Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5:29-41, 2005
23. Hughes RC: Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1473:172-185, 1999
24. Liu FT: Galectins: a new family of regulators of inflammation. Clin Immunol 97:79-88, 2000
25. Camby I, Belot N, Rorive S, et al: Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11:12-26, 2001
26. van den Brule FA, Waltregny D, Castronovo V: Increased expression of galectin-1 in carcinoma-associated stroma predicts poor out-come in prostate carcinoma patients. J Pathol 193:80-87, 2001
27. Cindolo L, Benvenuto G, Salvatore P, et al: Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas, Int J Cancer 84:39-43, 1999
28. Sanjuan X, Fernandez PL, Castells A, et al: Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113:1906-1915, 1997
29. He QY, Chen J, Kung HF, et al: Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Pro-teomics 4:271-278, 2004
30. Gillenwater A, Xu XC, el-Naggar AK, et al: Expression of galectins in head and neck squamous cell carcinoma. Head Neck 18:422-432, 1996
31. Kopitz J, von Reitzenstein C, Andre S, et al: Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 276:35917-35923, 2001
32. Tinari N, Kuwabara I, Huflejt ME, et al: Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation, Int J Cancer 91:167-172, 2001
33. van den Brule FA, Buicu C, Baldet M, et al: Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 209:760-767, 1995
34. Spiotto MT, Rowley DA, Schreiber H: Bystander elimination of antigen loss variants in established tumors. Nat Med 10:294-298, 2004
35. Chung CD, Patel VP, Moran M, et al: Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 165:3722-3729, 2000
36. Rabinovich GA, Ariel A, Hershkoviz R, et al: Specific inhibition of T-cell adhesion to extra-cellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97:100-106, 1999
37. Clausse N, van den Brule F, Waltregny D, et al: Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 3:317-325, 1999
38. Fuertes MB, Molinero LL, Toscano MA, et al: Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol Cell Biochem 267:177-185, 2004
39. Baum LG, Seilhamer JJ, Pang M, et al: Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj J 12:63-68, 1995
40. Pomerantz RG, Grandis JR: The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 31:734-743, 2004
41. Adam MF, Dorie MJ, Brown JM: Oxygen tension measurements of tumors growing in mice, Int J Radiat Oncol Biol Phys 45:171-180, 1999